In what looks like a natural cleaving of its sizeable business, Baxter International says it plans to create two independent global healthcare companies, effectively separating its biopharmaceuticals and medical products.
Baxter International Inc. has gained CE mark approval for its VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy.
Baxter International Inc. will acquire Swedish dialysis products company Gambro AB for a total consideration of a mere 26.5 billion SEK (approximately “a mere” $4.0 billion USD)
One specific LOT of Baxter’s sterile water for irrigation may be contaminated by a bacterium. As a precautionary measure the company is acting and UK’s regulatory body has issued a device alert calling for quarantining of identified product as further investigation is performed.
Baxter International Inc. has announced financial results for the second quarter and confirmed its full-year 2012 financial outlook. Sales increase of 4% year-on-year coupled with 1% income hike is in line with previous guidance.
UK competent authority the MHRA has issued a Medical Device Alert pertaining to Baxter’s Flogard and Colleague infusion pumps, one lot of which may have been incorrectly assembled.
Baxter’s previously advertised agreement to buy Synovis has now been consummated with the approval of Synovis’ shareholders.
Baxter International Inc. has announced that Jean-Luc Butel has been appointed corporate vice president and president, international and will assume his new role on February 20, 2012.
Baxter International Inc. and Synovis Life Technologies, Inc. have announced a definitive agreement for Baxter to acquire Synovis, a leading provider of biological and mechanical products for soft tissue repair used in a variety of surgical procedures.
Baxter Healthcare is providing over £200,000 of funding to two UK studies with the goal of establishing an improved evidence base for home dialysis treatment.
UK MHRA has issued a Medical Device Alert (MDA) on the Aquarius Haemofiltration Device manufactured by Nikkiso Europe GmBH and distributed by Baxter Healthcare.
Baxter International Inc. has announced that FDA has expanded the indication of ARTISS [Fibrin Sealant (Human)] to include adhering tissue flaps during facial rhytidectomy surgery (face-lift)
An increasing numbers of patients progressing to kidney disease and kidney failure place a financial strain on public health systems.
Baxter International Inc. announced today that the U.S. Food and Drug Administration has classified Baxter’s January 23, 2009 Urgent Device Correction letter to customers regarding U.S. COLLEAGUE® Volumetric Infusion Pumps as a Class I recall.
The Board of Directors of Baxter International Inc. today declared a quarterly dividend of $0.26 per share of Baxter common stock.
Baxter’s COSEAL Surgical Sealant gets CE marked and launched.